Try a new search

Format these results:

Searched for:

in-biosketch:true

person:millea51

Total Results:

44


Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients

Miller, Alexandra M; Szalontay, Luca; Bouvier, Nancy; Hill, Katherine; Ahmad, Hamza; Rafailov, Johnathan; Lee, Alex J; Rodriguez-Sanchez, M Irene; Yildirim, Onur; Patel, Arti; Bale, Tejus A; Benhamida, Jamal K; Benayed, Ryma; Arcila, Maria E; Donzelli, Maria; Dunkel, Ira J; Gilheeney, Stephen W; Khakoo, Yasmin; Kramer, Kim; Sait, Sameer F; Greenfield, Jeffrey P; Souweidane, Mark M; Haque, Sofia; Mauguen, Audrey; Berger, Michael F; Mellinghoff, Ingo K; Karajannis, Matthias A
BACKGROUND:Safe sampling of central nervous system tumor tissue for diagnostic purposes may be difficult if not impossible, especially in pediatric patients, and an unmet need exists to develop less invasive diagnostic tests. METHODS:We report our clinical experience with minimally invasive molecular diagnostics using a clinically validated assay for sequencing of cerebrospinal fluid (CSF) cell-free DNA (cfDNA). All CSF samples were collected as part of clinical care, and results reported to both clinicians and patients/families. RESULTS:We analyzed 64 CSF samples from 45 pediatric, adolescent and young adult (AYA) patients (pediatric = 25; AYA = 20) with primary and recurrent brain tumors across 12 histopathological subtypes including high-grade glioma (n = 10), medulloblastoma (n = 10), pineoblastoma (n = 5), low-grade glioma (n = 4), diffuse leptomeningeal glioneuronal tumor (DLGNT) (n = 4), retinoblastoma (n = 4), ependymoma (n = 3), and other (n = 5). Somatic alterations were detected in 30/64 samples (46.9%) and in at least one sample per unique patient in 21/45 patients (46.6%). CSF cfDNA positivity was strongly associated with the presence of disseminated disease at the time of collection (81.5% of samples from patients with disseminated disease were positive). No association was seen between CSF cfDNA positivity and the timing of CSF collection during the patient's disease course. CONCLUSIONS:We identified three general categories where CSF cfDNA testing provided additional relevant diagnostic, prognostic, and/or therapeutic information, impacting clinical assessment and decision making: (1) diagnosis and/or identification of actionable alterations; (2) monitor response to therapy; and (3) tracking tumor evolution. Our findings support broader implementation of clinical CSF cfDNA testing in this population to improve care.
PMID: 35148412
ISSN: 1523-5866
CID: 5671142

Accelerated Implementation of a Virtual Neurology Clerkship Amid a Global Crisis

Govindarajan, Raghav; Vu, Anh-Thu N; Salas, Rachel Marie E; Miller, Alexandra Michelle; Sandness, David J; Said, Rana R; Southerland, Andrew M; Fernandez, Andres; Romano, Sofia; Sennott, Brianna J; Patino-Murillas, Jorge; Soni, Madhu; ,
The standard neurology clinical experience in medical school focuses primarily on bedside patient encounters; however, the limitations of the clinical environment due to the current COVID-19 pandemic have accelerated the need for virtual curriculum development. To provide guidance to Neurology clerkship directors during this unprecedented time, the American Academy of Neurology (AAN) Undergraduate Education Subcommittee (UES) formed a workgroup to develop an outline for a virtual curriculum, provide recommendations, and describe models of integrating virtual curricula into the neurology clerkship. In this overview, we discuss different methods of virtual instruction, hybrid models of clerkship training and the challenges to its implementation, professionalism issues, and modification of feedback and assessment techniques specific to the virtual learning environment. We also offer suggestions for implementation of a hybrid virtual curriculum into the neurology clerkship. The virtual curriculum is intended to supplement the core neurology in-person clinical experience and should not be used for shortening or replacing the required neurology clinical clerkship.
PMID: 34921103
ISSN: 1526-632x
CID: 5671122

Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study

Schaff, Lauren R; Lobbous, Mina; Carlow, Dean; Schofield, Ryan; Gavrilovic, Igor T; Miller, Alexandra M; Stone, Jacqueline B; Piotrowski, Anna F; Sener, Ugur; Skakodub, Anna; Acosta, Edward P; Ryan, Kevin J; Mellinghoff, Ingo K; DeAngelis, Lisa M; Nabors, Louis B; Grommes, Christian
BACKGROUND:High-dose methotrexate (HD-MTX) has broad use in the treatment of central nervous system (CNS) malignancies but confers significant toxicity without inpatient hydration and monitoring. Glucarpidase is a bacterial recombinant enzyme dosed at 50 units (u)/kg, resulting in rapid systemic MTX clearance. The aim of this study was to demonstrate feasibility of low-dose glucarpidase to facilitate MTX clearance in patients with CNS lymphoma (CNSL). METHODS:and glucarpidase 2000 or 1000u 24 h later. Treatments repeated every 2 weeks up to 8 cycles. RESULTS:Fifty-five treatments were administered. Glucarpidase 2000u yielded > 95% reduction in plasma MTX within 15 min following 33/34 doses (97.1%) and glucarpidase 1000u yielded > 95% reduction following 15/20 doses (75%). Anti-glucarpidase antibodies developed in 4 patients and were associated with MTX rebound. In CSF, glucarpidase was not detected and MTX levels remained cytotoxic after 1 (3299.5 nmol/L, n = 8) and 6 h (1254.7 nmol/L, n = 7). Treatment was safe and well-tolerated. Radiographic responses in 6 of 8 patients (75%) were as expected following MTX-based therapy. CONCLUSIONS:This study demonstrates feasibility of planned-use low-dose glucarpidase for MTX clearance and supports the hypothesis that glucarpidase does not impact MTX efficacy in the CNS. CLINICAL TRIAL REGISTRATION/BACKGROUND:NCT03684980 (Registration date 26/09/2018).
PMCID:8756618
PMID: 35027038
ISSN: 1471-2407
CID: 5671132

Neurology podcast utilization during the COVID-19 pandemic

Siegler, James E; Boreskie, Patrick E; Strowd, Roy; Rook, Robert; Goss, Adeline; Al-Mufti, Fawaz; Rossow, Bonnie; Miller, Alexandra; Chamberlain, Amanda; London, Zachary; Hurley, Jennifer; Geocadin, Romergryko; Richie, Megan; Isaacson, Richard; Rybinnik, Igor; Chan, Teresa M
BACKGROUND:As medical education shifted to a virtual environment during the early coronavirus disease 2019 (COVID-19) pandemic, we evaluated how neurology podcasting may have been utilized during this period, and which features of podcasts have been more highly sought by a medical audience. METHODS:We conducted a retrospective analysis of neurology-themed blogs and/or podcasts between April 2019 and May 2020. Programs were eligible if they reported mean monthly downloads > 2000, were affiliated with an academic society, or offered continuing medical education credit. Thirty-day download counts were compared between study months, with adjustment for multiple testing. Exploratory analyses were performed to determine which podcast features were associated with higher downloads. RESULTS: = 0.80). The non-significant increase in overall downloads during April 2020 corresponded to an increase in unique episodes during that month (r = 0.48, p = 0.003). There was no difference in 30-day downloads among episodes including COVID-19 content versus not (median 1979 [IQR 791-2873] vs. 1171 [IQR 405-2665], p = 0.28). CONCLUSIONS:In this unique, exploratory study of academic neurology-themed podcasts, there was no significant increase in episode downloads during the early COVID-19 pandemic. A more comprehensive analysis of general and subspecialty medical podcasts is underway.
PMCID:8357627
PMID: 34383158
ISSN: 1590-3478
CID: 5671112

Education Research: NeuroBytes: A New Rapid, High-Yield e-Learning Platform for Continuing Professional Development in Neurology

Lavette, Laura E; Miller, Alexandra; Rook, Bobby; London, Zachary; Cook, Calli; Merkler, Alexander E; Santini, Veronica; Ruff, Ilana Marie; Kraakevik, Jeff; Smith, Don; Anderson, Wayne E; Johnson, Stacy L; Yan, Peter Z; Sweeney, Joan; Chamberlain, Amanda; Rogers-Baggett, Beth; Isaacson, Richard; Strowd, Roy E
OBJECTIVE:To determine whether NeuroBytes is a helpful e-Learning tool in neurology through usage, viewer type, estimated time and cost of development, and postcourse survey responses. BACKGROUND:A sustainable Continuing Professional Development (CPD) system is vital in neurology due to the field's expanding therapeutic options and vulnerable patient populations. In an effort to offer concise, evidence-based updates to a wide range of neurology professionals, the American Academy of Neurology (AAN) launched NeuroBytes in 2018. NeuroBytes are brief (<5 minutes) videos that provide high-yield updates to AAN members. METHODS:NeuroBytes was beta tested from August 2018 to December 2018 and launched for pilot circulation from January 2019 to April 2019. Usage was assessed by quantifying course enrollment and completion rates; feasibility by cost and time required to design and release a module; appeal by user satisfaction; and effect by self-reported change in practice. RESULTS:A total of 5,130 NeuroBytes enrollments (1,026 ± 551/mo) occurred from January 11, 2019, to May 28, 2019, with a median of 588 enrollments per module (interquartile range, 194-922) and 37% course completion. The majority of viewers were neurologists (54%), neurologists in training (26%), and students (8%). NeuroBytes took 59 hours to develop at an estimated $77.94/h. Of the 1,895 users who completed the survey, 82% were "extremely" or "very likely" to recommend NeuroBytes to a colleague and 60% agreed that the depth of educational content was "just right." CONCLUSIONS:NeuroBytes is a user-friendly, easily accessible CPD product that delivers concise updates to a broad range of neurology practitioners and trainees. Future efforts will explore models where NeuroBytes combines with other CPD programs to affect quality of training and clinical practice.
PMID: 33931531
ISSN: 1526-632x
CID: 5671092

A case series of extraneural metastatic glioblastoma at Memorial Sloan Kettering Cancer Center [Case Report]

Noch, Evan K; Sait, Sameer F; Farooq, Shama; Trippett, Tanya M; Miller, Alexandra M
BACKGROUND:Extraneural metastasis of glioma is a rare event, often occurring in patients with advanced disease. Genomic alterations associated with extraneural glioma metastasis remain incompletely understood. METHODS:Ten patients at Memorial Sloan Kettering Cancer Center diagnosed with extraneural metastases of glioblastoma (9 patients) and gliosarcoma (1 patient) from 2003 to 2018 were included in our analysis. Patient characteristics, clinical course, and genomic alterations were evaluated. RESULTS:Patient age at diagnosis ranged from 14 to 73, with 7 men and 3 women in this group. The median overall survival from initial diagnosis and from diagnosis of extraneural metastasis was 19.6 months (range 11.2 to 57.5 months) and 5 months (range 1 to 16.1 months), respectively. The most common site of extraneural metastasis was bone, with other sites being lymph nodes, dura, liver, lung, and soft tissues. All patients received surgical resection and radiation, and 9 patients received temozolomide, with subsequent chemotherapy appropriate for individual cases. 1 patient had an Ommaya and then ventriculoperitoneal shunt placed, and 1 patient underwent craniectomy for cerebral edema associated with a brain abscess at the initial site of resection. Genomic analysis of primary tumors and metastatic sites revealed shared and private mutations with a preponderance of tumor suppressor gene alterations, illustrating clonal evolution in extraneural metastases. CONCLUSIONS:Several risk factors emerged for extraneural metastasis of glioblastoma and gliosarcoma, including sarcomatous dedifferentiation, disruption of normal anatomic barriers during surgical resection, and tumor suppressor gene alterations. Next steps with this work include validation of these genomic markers of glioblastoma metastases in larger patient populations and the development of preclinical models. This work will lead to a better understanding of the molecular mechanisms of metastasis to develop targeted treatments for these patients.
PMCID:8153825
PMID: 34055380
ISSN: 2054-2577
CID: 5671102

Clinical Experience of Cerebrospinal Fluid-Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling

Bale, Tejus A; Yang, Soo-Ryum; Solomon, James P; Nafa, Khedoudja; Middha, Sumit; Casanova, Jacklyn; Sadowska, Justyna; Skakodub, Anna; Ahmad, Hamza; Yu, Helena A; Riely, Greg J; Kris, Mark G; Chandarlapaty, Sarat; Rosenblum, Marc K; Gavrilovic, Igor; Karajannis, Matthias A; Pentsova, Elena; Miller, Alexandra; Boire, Adrienne; Mellinghoff, Ingo; Berger, Michael F; Zehir, Ahmet; Ladanyi, Marc; Benayed, Ryma; Arcila, Maria E
Cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) offers unique opportunities for genomic profiling of tumors involving the central nervous system but remains uncommonly used in clinical practice. We describe our clinical experience using cfDNA from CSF for routine molecular testing using Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (targeting 468 cancer-related genes). In all, 148 cfDNA samples were assessed, comparing results of cfDNA versus genomic DNA (gDNA; gDNA from cell pellets) derived from the same CSF sample and the primary tumor. Of these, 71.6% (106/148) were successfully sequenced. Somatic alterations (mutations and fusions) were observed in 70.8% (75/106) of the samples; 97.3% (73/75) comprised variants confirming central nervous system involvement by a previously diagnosed tumor, 14.7% (11/75) had additional variants consistent with a therapy-related resistance mechanism, and 2.7% (2/75) had variants that independently diagnosed a new primary. Among samples with paired cfDNA and gDNA sequencing results, cfDNA was more frequently positive for at least one mutation [43.6% (55/126) versus 19.8% (25/126)] and harbored 1.6× more mutations (6.94 versus 4.65; P = 0.005), with higher mean variant allele fractions (41.1% versus 13.0%; P < 0.0001). Among mutation-positive cfDNAs, the corresponding gDNA was frequently negative (44.6%; 25/55) or failed sequencing (17.8%; 9/55). Routine molecular profiling of cfDNA is superior to gDNA from CSF, facilitating the capture of mutations at high variant allele frequency, even in the context of a negative cytology.
PMCID:8207471
PMID: 33781965
ISSN: 1943-7811
CID: 5671082

Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions

Mata, Douglas A; Benhamida, Jamal K; Lin, Andrew L; Vanderbilt, Chad M; Yang, Soo-Ryum; Villafania, Liliana B; Ferguson, Donna C; Jonsson, Philip; Miller, Alexandra M; Tabar, Viviane; Brennan, Cameron W; Moss, Nelson S; Sill, Martin; Benayed, Ryma; Mellinghoff, Ingo K; Rosenblum, Marc K; Arcila, Maria E; Ladanyi, Marc; Bale, Tejus A
A subset of glioblastomas (GBMs) harbors potentially druggable oncogenic FGFR3-TACC3 (F3T3) fusions. However, their associated molecular and clinical features are poorly understood. Here we analyze the frequency of F3T3-fusion positivity, its associated genetic and methylation profiles, and its impact on survival in 906 IDH-wildtype GBM patients. We establish an F3T3 prevalence of 4.1% and delineate its associations with cancer signaling pathway alterations. F3T3-positive GBMs had lower tumor mutational and copy-number alteration burdens than F3T3-wildtype GBMs. Although F3T3 fusions were predominantly mutually exclusive with other oncogenic RTK pathway alterations, they did rarely co-occur with EGFR amplification. They were less likely to harbor TP53 alterations. By methylation profiling, they were more likely to be assigned the mesenchymal or RTK II subclass. Despite being older at diagnosis and having similar frequencies of MGMT promoter hypermethylation, patients with F3T3-positive GBMs lived about 8 months longer than those with F3T3-wildtype tumors. While consistent with IDH-wildtype GBM, F3T3-positive GBMs exhibit distinct biological features, underscoring the importance of pursuing molecular studies prior to clinical trial enrollment and targeted treatment.
PMCID:7653727
PMID: 33168106
ISSN: 2051-5960
CID: 5671062

Reevaluation of the Frequent Use of PD-1 Checkpoint Inhibitors for Treatment of Glioblastoma [Comment]

Miller, Alexandra M; DeAngelis, Lisa M
PMID: 32453825
ISSN: 1538-3598
CID: 5770422

Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR

Young, Robert J; Demétrio De Souza França, Paula; Pirovano, Giacomo; Piotrowski, Anna F; Nicklin, Philip J; Riedl, Christopher C; Schwartz, Jazmin; Bale, Tejus A; Donabedian, Patrick L; Kossatz, Susanne; Burnazi, Eva M; Roberts, Sheryl; Lyashchenko, Serge K; Miller, Alexandra M; Moss, Nelson S; Fiasconaro, Megan; Zhang, Zhigang; Mauguen, Audrey; Reiner, Thomas; Dunphy, Mark P
Background/UNASSIGNED:F]PARPi, as a diagnostic tool to differentiate between brain cancers and treatment-related changes. Methods/UNASSIGNED:F]PARPi acquisition on a dedicated positron emission tomography/magnetic resonance (PET/MR) scanner. Lesion diagnosis was established by pathology when available or by Response Assessment in Neuro-Oncology (RANO) or RANO-BM response criteria. Resected tissue also underwent PARPi-FL staining and PARP1 immunohistochemistry. Results/UNASSIGNED:F]PARPi uptake on PET/MR in active brain cancers and low uptake in treatment-related changes independent of blood-brain barrier disruption. Immunohistochemistry results confirmed higher PARP1 expression in cancerous than in noncancerous tissue. Specificity was also corroborated by blocking fluorescent tracer uptake with an excess unlabeled PARP inhibitor in patient cancer biospecimen. Conclusions/UNASSIGNED:F]PARPi as a diagnostic tool to evaluate patients with brain cancers and possible treatment-related changes.
PMCID:7758909
PMID: 33392502
ISSN: 2632-2498
CID: 4840762